V116 shows safety and immunogenicity in high-risk children for pneumococcal disease
The phase 3 study demonstrated that V116 met noninferiority and superiority criteria for immunogenicity compared to PPSV23 in children with chronic conditions.
Therapeutic Area
Therapeutic area intelligence for Pneumococcal Vaccination with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.